Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 07, 2021 07:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors

--NGM707, a ILT2/ILT4 dual antagonistic antibody, is engineered to reverse myeloid suppression with the goal of improving patient immune responses to tumors-- --Study to evaluate potential of NGM707...
July 01, 2021 07:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases

Merck and NGM will continue their research, discovery and development collaboration with a narrower scope, focused primarily on retinal and cardiovascular and metabolic (CVM) targets of interest to...
June 07, 2021 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Present at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
May 24, 2021 07:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH

Study did not meet primary endpoint of fibrosis improvement by >1 stage with no worsening of NASH versus placeboStatistical significance achieved versus placebo on certain secondary endpoints,...
May 23, 2021 18:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH

SOUTH SAN FRANCISCO, Calif., May 23, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30...
May 06, 2021 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results

Expect to report topline data from Phase 2b ALPINE 2/3 clinical trial of aldafermin in patients with NASH with F2 and F3 liver fibrosis in the second quarterContinued enrollment in Phase 2 CATALINA...
April 28, 2021 16:15 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
March 04, 2021 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results

•Significant progress made across liver and metabolic diseases, retinal diseases and cancer during fourth quarter 2020: •Presented first-in-human results from Phase 1 clinical trial of NGM621 in...
March 02, 2021 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer

--Placebo-controlled study to evaluate potential of NGM120, a novel inhibitor of GDF15/GFRAL pathway, to treat cancer and cancer-related cachexia-- --Cachexia, a wasting syndrome, is a common...
February 25, 2021 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Present at the Cowen 41st Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...